A NOVEL NUCLEAR MITOTIC PHOSPHOPROTEIN: MITOSIN

WIPO Patent Application WO1995011309

A3

A novel purified phosphoprotein designated mitosin is provided by this invention. Also provided is the amino acid sequence of mitosin, active fragments of mitosin, and a nucleic acid molecule encoding mitosin. Diagnostic and therapeutic methods of using the protein and nucleic acid molecule are also provided. The nucleic acid molecules are useful to recombinantly produce mitosin and for use as probes. The compositions and methods of this invention are based on the discovery that the intracellular presence of mitosin is necessary for the cell to enter the M phase of mitosis, and that the degradation of mitosin is necessary for the cell to advance to the next stage. Thus, an anti-mitsoin antibody, or a mutant or non-functional analog of mitosin, would inhibit the mitotic cell cycle by preventing cells from entering the M phase, and overexpression of mitosin, or a functional equivalent thereof, would inhibit the cycle by preventing cells from leaving the M phase. Such overexpression could be achieved either by addition of the protein or through gene therapy, i.e., delivery of a gene encoding the protein or a functional equivalent thereof.

JP2015096556	IMPROVED TREATMENT METHOD FOR RETINAL DEGENERATION DISEASE
JP2023520468	ACE2Having described in detail the subject matter of this disclosure and its advantages, it should be understood that various changes, substitutions and alterations may be made herein without departing from the spirit and scope of this disclosure. Moreover, the scope of the present application is not intended to be limited to the particular embodiments of the process, machine, manufacture and composition of matter, means, methods and steps described in the specification. Those skilled in the art will recognize any currently existing or later developed subject matter of the present disclosure that performs substantially the same function or achieves substantially the same results as the corresponding embodiments described herein. , process, machine, manufacture, composition of matter, means, method, or step can be utilized in accordance with the subject matter of the disclosure. Accordingly, the appended claims are intended to include within their scope such processes, machines, manufacture, compositions of matter, means, methods, or steps.
JP2008104466	TREATMENT FOR DIABETES

ZHU XEULIANG (US)
LEE WEN-HWA (US)

PCT/US1994/012162

June 08, 1995

October 24, 1994

Click for automatic bibliography generation  

UNIV TEXAS (US)
ZHU XEULIANG (US)
LEE WEN HWA (US)

A61K35/12; A61K38/00; A61K38/45; A61K39/395; A61K48/00; A61P13/02; A61P15/00; A61P17/00; A61P35/00; G01N33/53; A61P35/02; C07H21/04; C07K14/47; C07K16/18; C12N1/21; C12N15/09; C12P21/02; C12P21/08; G01N33/566; (IPC1-7): C12N15/85; C12N15/12; C12N15/13; C12N5/16; C07K14/47; A61K39/395; A61K38/17; A61K48/00; C12P21/02

BUCHKOVICH ET AL.: "The retinoblastoma protein is phosphorylated during specific phases of the cell cycle", CELL, vol. 58, 22 September 1989 (1989-09-22), pages 1097 - 1105
SHAN ET AL.: "Molecular cloning of cellular genes encoding retinoblastoma-associated proteins : identification of a gene with properties of the transcription factor E2F", MOL. CELL. BIOL., vol. 12, no. 12, December 1992 (1992-12-01), pages 5620 - 5631

View/Download PDF      PDF Help

Previous Patent: MAMMAL WITH ENHANCED LIVER EXPRESSION OF A TRANSGENE

Next Patent: ANTIFUNGAL ANTIBIOTIC CEPACIDINE A